Although investor concerns about the MedTech Sector have been based on expected declines in obesity rates with the surging adoption of GLP-1s, IQVIA MedTechs analysis of the data tells a different story, overall, that - to date - obesity diagnoses remain stable during the rise of GLP-1 uptake as depicted below: As a result, the resilience of obesity diagnosis occurring despite the rising uptake of GLP-1s should serve as a positive general signal for MedTech industry players to counter investor concerns about the potential of reduced demand, or that the demand may be net-neutral, rather than a sudden decline
From nausea and indigestion to ozempic face and lessened cravings, they really run the gamut
These growing cases and raised efficacy with enhanced glycemic control and weight loss make them a preferred treatment option for many patients
FAERS, FDA Adverse Event Reporting System
Part of the Modere Body Transformation Collection Curb is part of a complete body transformation collection from Modere, which includes protein, CLA, a stimulant-based fat burner, collagen, and amino acids
Vokinger KN, Nussli E, Dusetzina SB
